Author:
La Grenade Lois,Mockenhaupt Maja,Phillips Elizabeth
Reference14 articles.
1. Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton B (2011) Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol 18:e106–e120
2. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY, Ro LS, Lu CT, Chu CC, Tsai JJ, Su YH, Lan SH, Sung SF, Lin SY, Chuang HP, Huang LC, Chen YJ, Tsai PJ, Liao HT, Lin YH, Chen CH, Chung WH, Hung SI, Wu JY, Chang CF, Chen L, Chen YT, Shen CY, Taiwan SJS Consortium (2011) Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364(12):1126–1133
3. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982):486
4. Davis RL, Gallagher MA, Asgari MM, Eide MJ, Margolis DJ, Macy E, Burmester JK, Selvam N, Boscarino JA, Cromwell LF, Feigelson HS, Kuntz JL, Pawloski PA, Penfold RB, Raebel MA, Sridhar G, Wu A, La Grenade LA, Pacanowski MA, Pinheiro SP (2015) Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases. Pharmacoepidemiol Drug Saf 24(7):684–692
5. Hamilton GM, Fish J (2013) Pediatric toxic epidermal necrolysis: an institutional review of patients admitted to an intensive care unit. J Burn Care Res 34(6):e351–e358